Autopsy report · NCT01113229

Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage

“reason of halt prematurely: futility of the trial”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 4 years 9 months before it stopped.
• 1,721 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Hemorrhage; Complicating Delivery

Interventions

Misoprostol

Participants

1,721

Sites

1

Countries

France

Trials that died the same way

• Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
  “The trial was stopped for futility in view of the results of the anticipated analysis” (72% match in meaning)
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
  “Trial stopped for futility” (70% match in meaning)
• Stanford Accelerated Recovery Trial (START)
  “Trial met futility stopping point” (65% match in meaning)
• Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
  “Futility analysis did not support continuation of the trial” (65% match in meaning)
• Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
  “The trial closed early due to slow accrual.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.